Technical Analysis for CRIS - Curis, Inc.

Grade Last Price % Change Price Change
grade C 1.48 -2.63% -0.04
CRIS closed down 2.63 percent on Friday, May 24, 2019, on 8 percent of normal volume. The stock exhibited some range contraction during this trading session as price made an NR7 -- narrowest range of the last seven sessions. Due to the stock's strong downtrend, it may remain oversold for a while. So, if you're looking for a reason to buy, don't put too much weight on it being oversold.

Trend Table & Recent Signals
ADX Long-Term Intermediate-Term Short-Term
Strong Up Down Down
See historical CRIS trend table...

Date Alert Name Type % Chg
New Downtrend Bearish 0.00%
NR7 Range Contraction 0.00%
Lower Bollinger Band Walk Weakness 0.00%
Stochastic Reached Oversold Weakness 0.00%
Inside Day Range Contraction 0.00%
Wide Bands Range Expansion 0.00%
Lower Bollinger Band Touch Weakness 0.00%
Oversold Stochastic Weakness 0.00%
200 DMA Support Bullish -2.63%
Hammer Candlestick Bullish -2.63%

Older signals for CRIS ...

Get a Trading Sidekick!

Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.
Configure default chart indicators
Basic chart:

Curis, Inc. engages in the research, development, and commercialization of cancer therapeutics. Its principal product is Erivedge capsule for treatment of adults with basal cell carcinoma (BCC) that has spread to other parts of the body or that has come back after surgery. The company also develops Erivedge, which is in phase II clinical trial for the treatment of operable nodular BCC; CUDC-427, a small molecule that has completed phase I clinical trial to promote cancer cell death in breast cancer and other solid tumors, and hematological cancers; and CUDC-907, a small molecule, which is in phase I clinical trial for the treatment of advanced lymphoma and multiple myeloma. In addition, it develops CUDC-101 that has completed phase I dose escalation clinical trial for the treatment of refractory solid tumors; and phase I expansion trial for the treatment of breast, gastric, head and neck, liver, or non-small cell lung cancers. Further, the company develops Debio 0932 that is in phase Ib expansion study for the treatment of solid tumors; and in a phase I/II clinical trial for the treatment of advanced non-small cell lung cancer. It has collaborations with Genentech, Inc. for the development of Erivedge; and Debiopharm S.A. for the development and commercialization of Debio 0932. Curis, Inc. was founded in 2000 and is headquartered in Lexington, Massachusetts.
Cancer Drugs Surgery Solid Tumors Drug Discovery Breast Cancer Multiple Myeloma Cancer Therapeutics Hematological Cancers Phosphoinositide 3 Kinase Inhibitor Protein Kinase Inhibitors Advanced Non Small Cell Lung Cancer Refractory Solid Tumors
Is CRIS a Buy, Sell or Hold?
Indicator Bull Case Neutral / Hold Bear Case
50 DMA
200 DMA
ADX Trend
Oversold / Overbought
Relative Strength
Summary: Counts: 1 bullish, 2 bearish and 2 neutral indicators. You may wish to incorporate that into your trading strategies.
Indicator Value
52 Week High 3.33
52 Week Low 0.6
Average Volume 705,222
200-Day Moving Average 1.4506
50-Day Moving Average 1.8393
20-Day Moving Average 1.7718
10-Day Moving Average 1.668
Average True Range 0.1268
ADX 25.73
+DI 13.2954
-DI 28.9785
Chandelier Exit (Long, 3 ATRs ) 1.6096
Chandelier Exit (Short, 3 ATRs ) 1.8004
Upper Bollinger Band 2.0831
Lower Bollinger Band 1.4605
Percent B (%b) 0.03
BandWidth 35.139406
MACD Line -0.0827
MACD Signal Line -0.0385
MACD Histogram -0.0442
Fundamentals Value
Market Cap 212.94 Million
Num Shares 144 Million
EPS -0.50
Price-to-Earnings (P/E) Ratio -2.96
Price-to-Sales 27.52
Price-to-Book 24.84
PEG Ratio 0.00
Dividend 0.00
Dividend Yield 0.00%
Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
Resistance 4 (R4) 1.59
Resistance 3 (R3) 1.59 1.56 1.57
Resistance 2 (R2) 1.56 1.53 1.56 1.56
Resistance 1 (R1) 1.52 1.52 1.51 1.52 1.56
Pivot Point 1.49 1.49 1.48 1.49 1.49
Support 1 (S1) 1.45 1.46 1.44 1.45 1.40
Support 2 (S2) 1.42 1.45 1.42 1.40
Support 3 (S3) 1.38 1.42 1.39
Support 4 (S4) 1.38